Chemical Diversity of ADC Payloads: An In-Depth Analysis from Mechanisms of Action to R&D Strategies

The Core Role of Payload in ADCs

Antibody-drug conjugates (ADCs) achieve the concept of precision chemotherapy by delivering small-molecule cytotoxic drugs (Payloads) to tumor cells through antibody targeting. The chemical properties of the Payload directly determine the potency, drug resistance, and systemic toxicity of the ADC, making it a key module that requires balancing in molecular design. An ideal Payload should possess high cytotoxicity (generally with IC50 in the nanomolar to picomolar range), appropriate water solubility, plasma stability, and the ability to be effectively released within target cells. In recent years, the chemical space of Payloads has expanded from traditional microtubule inhibitors to a variety of novel mechanisms of action, driving the diversity of ADC clinical pipelines.

Common Payload Mechanisms of Action and Chemical Types

Microtubule inhibitor Payloads, such as maytansine derivatives (DM1, DM4) and auristatin derivatives (MMAE, MMAF), interfere with mitosis by inhibiting microtubule polymerization or stabilizing microtubules, and are the most widely used type in marketed ADCs. DNA-damaging agents such as calicheamicin, duocarmycin (DUO), and pyrrolobenzodiazepine (PBD) dimers generally exhibit higher cytotoxicity than microtubule inhibitors and are suitable for tumors with low antigen expression or drug resistance. Topoisomerase I inhibitors such as camptothecin derivatives (DXd, SN-38) have attracted considerable attention in recent years due to the success of Enhertu, and their unique mechanism of action and high permeability help overcome tumor heterogeneity. In addition, novel Payloads such as RNA polymerase inhibitors (e.g., α-amanitin) and Bcl-xL inhibitors are in early development, aiming to expand the therapeutic spectrum of ADCs.

Key Parameters for Payload Screening

During Payload selection, in addition to cytotoxic potency, medicinal chemists must comprehensively evaluate the following dimensions: 1) Hydrophobicity: excessively hydrophobic Payloads tend to cause ADC aggregation and accelerated clearance, and are detrimental to blood stability; 2) Conjugatability: Payloads need modifiable chemical groups (e.g., amino, sulfhydryl) to attach to linkers, without affecting targeting activity and drug release after conjugation; 3) Membrane permeability and bystander effect: Payloads with higher membrane permeability (e.g., MMAE) can diffuse to adjacent tumor cells to exert a bystander killing effect, making them suitable for heterogeneous tumors; whereas membrane-impermeable Payloads (e.g., MMAE-F, PBD) are confined within target cells, reducing systemic toxicity. 4) Drug resistance evasion: selecting Payloads with no cross-resistance to commonly used chemotherapeutic agents (e.g., PBD targeting the DNA minor groove, which is not easily effluxed by MDR pumps) can enhance treatment durability.

Linker-Payload Combination Optimization Strategies

The linker serves as the "release switch" for the Payload, and its design must be collaboratively optimized with the physicochemical properties of the Payload. Cleavable linkers (e.g., valine-citrulline dipeptide, β-glucuronidase-sensitive bonds, pH-sensitive hydrazone bonds) utilize intracellular lysosomal enzymes or acidic environments to release the parent drug, but premature plasma cleavage must be avoided; non-cleavable linkers (e.g., SMCC, MC) rely on antibody degradation to release the amino acid-linker-Payload complex, and the Payload must still retain activity. In recent years, site-specific conjugation technology combined with homogeneous DAR (drug-to-antibody ratio) Payload-linker combinations has helped improve the pharmacokinetics and therapeutic index of ADCs. For example, conjugation based on non-natural amino acids or enzymatic transglutaminase can achieve homogeneous ADCs with a DAR of 2, reducing the aggregation and clearance issues associated with high DAR.

Future Trends and Challenges

Payload development is advancing toward lower toxicity (but higher than traditional chemotherapeutic agents), stronger bystander effects, and variable payload types. High-molecular-weight Payloads, dual-payload ADCs (carrying two payloads with different mechanisms), and ADCs based on PROTACs or immune agonists represent cutting-edge directions. However, the synthetic complexity of Payloads and the safety risks associated with high potency (e.g., occupational exposure, cross-contamination) impose higher requirements on manufacturing and quality control, urgently necessitating continuous updates to industry standards and regulatory guidance. Overall, the chemical design of Payloads is a core element of ADC differentiation and competitive advantage, and medicinal chemistry researchers must seek the optimal balance among potency, stability, and toxicity.